One- & Two-Year Survival Rates of 94% and 88% Announced from Phase 1b Trial of Investigational PD-1 Checkpoint Inhibitor Nivolumab and YervoyÂ® (ipilimumab) in Advanced Melanoma; Ongoing Phase 2/3 Trials to Confirm Results